# REGN catalysts: REGENERON PHARMACEUTICALS, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/regn/catalysts

> REGENERON PHARMACEUTICALS, INC. (REGN) has 100 upcoming catalysts. The next is the REGN7999 topline data readout, Dec 2026 to Mar 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | REGENERON PHARMACEUTICALS, INC. |
| Ticker | REGN (Nasdaq) |
| SEC CIK | 872589 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/regn |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| March 28, 2017 | [Dupixent (dupilumab) FDA approval](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed, approved | "BLA761055 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20170328, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22)) |
| September 28, 2018 | [Libtayo (cemiplimab-rwlc) FDA approval](https://sec-api.dev/pdufa/cemiplimab-rwlc) | REGN |  | completed, approved | "BLA761097 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20180928, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product LIBTAYO (CEMIPLIMAB-RWLC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761097%22)) |
| May 26, 2020 | [Dupixent (dupilumab) label expansion decision](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed, approved | "BLA761055 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20200526, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22)) |
| June 18, 2020 | [Dupixent (dupilumab) label expansion decision](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed, approved | "BLA761055 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20200618, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22)) |
| June 25, 2020 | [Libtayo (cemiplimab-rwlc) label expansion decision](https://sec-api.dev/pdufa/cemiplimab-rwlc) | REGN |  | completed, approved | "BLA761097 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20200625, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product LIBTAYO (CEMIPLIMAB-RWLC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761097%22)) |
| October 14, 2020 | [Inmazeb (atoltivimab; maftivimab; odesivimab) FDA approval](https://sec-api.dev/pdufa/atoltivimab-maftivimab-odesivimab) | REGN |  | completed, approved | "BLA761169 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20201014, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product INMAZEB (ATOLTIVIMAB; MAFTIVIMAB; ODESIVIMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761169%22)) |
| February 9, 2021 | [Libtayo (cemiplimab-rwlc) label expansion decision](https://sec-api.dev/pdufa/cemiplimab-rwlc) | REGN |  | completed, approved | "BLA761097 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20210209, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product LIBTAYO (CEMIPLIMAB-RWLC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761097%22)) |
| February 11, 2021 | [Evkeeza (evinacumab-dgnb) FDA approval](https://sec-api.dev/pdufa/evinacumab-dgnb) | REGN |  | completed, approved | "BLA761181 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20210211, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product EVKEEZA (EVINACUMAB-DGNB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761181%22)) |
| February 22, 2021 | [Libtayo (cemiplimab-rwlc) label expansion decision](https://sec-api.dev/pdufa/cemiplimab-rwlc) | REGN |  | completed, approved | "BLA761097 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20210222, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product LIBTAYO (CEMIPLIMAB-RWLC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761097%22)) |
| April 1, 2021 | [Praluent (alirocumab) label expansion decision](https://sec-api.dev/pdufa/alirocumab) | REGN |  | completed, approved | "BLA125559 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20210401, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product PRALUENT (ALIROCUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125559%22)) |
| June 14, 2021 | [Dupixent (dupilumab) label expansion decision](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed, approved | "BLA761055 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20210614, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22)) |
| October 20, 2021 | [Dupixent (dupilumab) label expansion decision](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed, approved | "BLA761055 SUPPL-31 (Efficacy): submission_status AP, submission_status_date 20211020, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22)) |
| May 20, 2022 | [Dupixent (dupilumab) label expansion decision](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed, approved | "BLA761055 SUPPL-40 (Efficacy): submission_status AP, submission_status_date 20220520, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22)) |
| June 7, 2022 | [Dupixent (dupilumab) label expansion decision](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed, approved | "BLA761055 SUPPL-42 (Efficacy): submission_status AP, submission_status_date 20220607, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22)) |
| September 28, 2022 | [Dupixent (dupilumab) label expansion decision](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed, approved | "BLA761055 SUPPL-44 (Efficacy): submission_status AP, submission_status_date 20220928, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22)) |
| November 8, 2022 | [Libtayo (cemiplimab-rwlc) label expansion decision](https://sec-api.dev/pdufa/cemiplimab-rwlc) | REGN |  | completed, approved | "BLA761097 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20221108, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product LIBTAYO (CEMIPLIMAB-RWLC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761097%22)) |
| February 8, 2023 | [PAVBLU® (aflibercept) label expansion decision](https://sec-api.dev/pdufa/aflibercept) | REGN |  | completed, approved | "BLA125387 SUPPL-75 (Efficacy): submission_status AP, submission_status_date 20230208, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product EYLEA (AFLIBERCEPT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125387%22)) |
| March 21, 2023 | [Evkeeza (evinacumab-dgnb) label expansion decision](https://sec-api.dev/pdufa/evinacumab-dgnb) | REGN |  | completed, approved | "BLA761181 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20230321, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product EVKEEZA (EVINACUMAB-DGNB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761181%22)) |
| April 28, 2023 | [Libtayo (cemiplimab-rwlc) label expansion decision](https://sec-api.dev/pdufa/cemiplimab-rwlc) | REGN |  | completed, approved | "BLA761097 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20230428, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product LIBTAYO (CEMIPLIMAB-RWLC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761097%22)) |
| June 27, 2023 | [PAVBLU® (aflibercept) complete response letter (CRL)](https://sec-api.dev/pdufa/aflibercept) | REGN |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22761355_2024_Orig1s000OtherActionLtrs.pdf%22)) |
| Aug 2023 | [Eylea® (eylea) FDA approval](https://sec-api.dev/pdufa/eylea) | REGN |  | completed, approved | "EYLEA HD was approved by the FDA in August 2023 and net product sales in 2024 were driven by the transition of patients from other anti-VEGF products, including EYLEA, as well as new patients naïve to anti-VEGF therapy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/exhibit991q42024.htm)) |
| August 18, 2023 | [PAVBLU® (aflibercept) FDA approval](https://sec-api.dev/pdufa/aflibercept) | REGN |  | completed, approved | "BLA761355 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20230818, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product EYLEA HD (AFLIBERCEPT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761355%22)) |
| August 18, 2023 | [Veopoz (pozelimab-bbfg) FDA approval](https://sec-api.dev/pdufa/pozelimab-bbfg) | REGN |  | completed, approved | "Veopoz \| pozelimab-bbfg \| 8/18/2023 \| To treat patients 1 year old and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE diseaseDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| January 12, 2024 | [Dupixent (dupilumab) label expansion decision](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed, approved | "BLA761055 SUPPL-55 (Efficacy): submission_status AP, submission_status_date 20240112, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22)) |
| January 25, 2024 | [Dupixent (dupilumab) label expansion decision](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed, approved | "BLA761055 SUPPL-57 (Efficacy): submission_status AP, submission_status_date 20240125, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22)) |
| March 8, 2024 | [Praluent (alirocumab) label expansion decision](https://sec-api.dev/pdufa/alirocumab) | REGN |  | completed, approved | "BLA125559 SUPPL-39 (Efficacy): submission_status AP, submission_status_date 20240308, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product PRALUENT (ALIROCUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125559%22)) |
| March 22, 2024 | [Ordspono™ (odronextamab) complete response letter (CRL)](https://sec-api.dev/pdufa/odronextamab) | REGN | relapsed/refractory FL and DLBCL due | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761303Original1_20240322.pdf%22)) |
| April 5, 2024 | [Libtayo (cemiplimab-rwlc) label expansion decision](https://sec-api.dev/pdufa/cemiplimab-rwlc) | REGN |  | completed, approved | "BLA761097 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20240405, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product LIBTAYO (CEMIPLIMAB-RWLC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761097%22)) |
| Aug 2024 | [Lynozyfic (linvoseltamab) complete response letter (CRL)](https://sec-api.dev/pdufa/linvoseltamab) | REGN |  | completed, complete response letter | "For example, in August 2024, the FDA issued a CRL concerning the Company's BLA for linvoseltamab in relapsed/refractory multiple myeloma due to findings from a pre-approval inspection at a third-party fill/finish provider for another company's product candidate." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/872589/000180422025000022/regn-20250331.htm)) |
| August 20, 2024 | [Lynozyfic (linvoseltamab-gcpt) complete response letter (CRL)](https://sec-api.dev/pdufa/linvoseltamab-gcpt) | REGN |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761400_20240820.pdf%22)) |
| August 26, 2024 | [PAVBLU® (aflibercept) FDA approval](https://sec-api.dev/pdufa/aflibercept) | REGN |  | completed, approved | "On August 26, 2024, the Company filed a patent infringement lawsuit against Sandoz Inc. ("Sandoz") in the United States District Court for the District of New Jersey alleging that Sandoz's filing for FDA approval of an aflibercept 2 mg biosimilar infringed certain Company patents." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/regn-20250930.htm)) |
| September 12, 2024 | [Dupixent (dupilumab) label expansion decision](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed, approved | "BLA761055 SUPPL-66 (Efficacy): submission_status AP, submission_status_date 20240912, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22)) |
| September 27, 2024 | [Dupixent (dupilumab) label expansion decision](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed, approved | "BLA761055 SUPPL-64 (Efficacy): submission_status AP, submission_status_date 20240927, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22)) |
| Jan 2025 | [Lynozyfic (linvoseltamab) NDA/BLA submission](https://sec-api.dev/pdufa/linvoseltamab) | REGN |  | completed | "•In January 2025, the Company resubmitted to the FDA the BLA for linvoseltamab, a bispecific antibody targeting BCMA and CD3, in relapsed/refractory (R/R) multiple myeloma following resolution of third-party manufacturing issues." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/exhibit991q42024.htm)) |
| Q1 2025 | [Eylea® (eylea) NDA/BLA submission](https://sec-api.dev/pdufa/eylea) | REGN |  | scheduled | "The Company plans to submit a sBLA for EYLEA HD for every four-week dosing and for retinal vein occlusion (RVO) in the first quarter of 2025 to potentially maximize dosing flexibility and address more retinal diseases." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-1.htm)) |
| Jan 2025 | [Ordspono™ (odronextamab) NDA/BLA submission](https://sec-api.dev/pdufa/odronextamab) | REGN |  | completed | "•In January 2025, the Company resubmitted to the FDA the BLA for odronextamab, a bispecific antibody targeting CD20 and CD3, in R/R follicular lymphoma." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/exhibit991q42024.htm)) |
| Feb 2025 | [Dupixent (dupilumab) NDA/BLA acceptance](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed | "In February 2025, the FDA accepted for priority review the supplemental Biologics License Application (sBLA) for Dupixent in bullous pemphigoid, with a target action date of June 20, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm)) |
| February 4, 2025 | [REGENERON PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/regn/catalysts) | REGN |  | completed | "Tarrytown, New York (February 4, 2025) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2024 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/exhibit991q42024.htm)) |
| Apr 2025 | [Dupixent (dupilumab) FDA approval](https://sec-api.dev/pdufa/dupilumab) | REGN | and adolescents aged 12 years and older with CSU | completed, approved | "•In April 2025, the FDA approved Dupixent for the treatment of adults and adolescents aged 12 years and older with CSU who remain symptomatic despite antihistamine treatment." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/exhibit991q22025.htm)) |
| Apr 2025 | [Fianlimab interim data readout](https://sec-api.dev/pdufa/fianlimab) | REGN |  | scheduled | "In April 2025, a pre-planned interim analysis was conducted on two ongoing Phase 2/3 studies evaluating the combination of fianlimab and cemiplimab in first-line advanced NSCLC." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/872589/000180422025000022/regn-20250331.htm)) |
| April 17, 2025 | [Dupixent (dupilumab) label expansion decision](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed, approved | "BLA761055 SUPPL-51 (Efficacy): submission_status AP, submission_status_date 20250417, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22)) |
| April 18, 2025 | [Dupixent (dupilumab) PDUFA date](https://sec-api.dev/pdufa/dupilumab) | REGN | and adolescents aged 12 years and older with chronic spontaneous urticaria | completed, approved | "•The FDA accepted for review the resubmission of an sBLA for Dupixent to treat adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment, with a target action date of April 18, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/exhibit991q42024.htm)) |
| April 20, 2025 | [REGENERON PHARMACEUTICALS, INC. PDUFA date](https://sec-api.dev/companies/regn/catalysts) | REGN |  | scheduled | "FDA decision on sBLA with two-year data for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) (target action date of April 20, 2025)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/exhibit991q42024.htm)) |
| April 20, 2025 | [Eylea® (eylea) PDUFA date](https://sec-api.dev/pdufa/eylea) | REGN |  | completed, complete response letter | "Longer term data in wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) are under FDA review with a PDUFA date of April 20, 2025 to potentially extend dosing intervals for EYLEA HD up to every-24 weeks." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-1.htm)) |
| April 23, 2025 | [Eylea® (eylea) complete response letter (CRL)](https://sec-api.dev/pdufa/eylea) | REGN |  | completed, complete response letter | "•The FDA issued a Complete Response Letter (CRL) for the EYLEA HD pre-filled syringe on April 23, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm)) |
| April 29, 2025 | [REGENERON PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/regn/catalysts) | REGN |  | completed | "Tarrytown, New York (April 29, 2025) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm)) |
| May 10, 2025 | [REGN1908 primary completion](https://sec-api.dev/pdufa/regn1908) | REGN | Allergic Conjunctivitis | completed | "NCT06602726 (A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-10 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06602726)) |
| Jun 2025 | [Dupixent (dupilumab) FDA approval](https://sec-api.dev/pdufa/dupilumab) | REGN | with bullous pemphigoid | completed, approved | "•In June 2025, the FDA approved Dupixent for the treatment of adults with bullous pemphigoid." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/exhibit991q22025.htm)) |
| June 2, 2025 | [REGN5381 primary completion](https://sec-api.dev/pdufa/regn5381) | REGN | Heart Failure | completed | "NCT05353166 (REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-02 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals; Results First Posted 2026-09-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05353166)) |
| June 18, 2025 | [Dupixent (dupilumab) label expansion decision](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed, approved | "BLA761055 SUPPL-70 (Efficacy): submission_status AP, submission_status_date 20250618, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22)) |
| June 20, 2025 | [Dupixent (dupilumab) PDUFA date](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed, approved | "In February 2025, the FDA accepted for priority review the supplemental Biologics License Application (sBLA) for Dupixent in bullous pemphigoid, with a target action date of June 20, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm)) |
| 2H 2025 | [Fianlimab NDA/BLA submission](https://sec-api.dev/pdufa/fianlimab) | REGN |  | scheduled | "Results from the first Phase 3 study in first-line metastatic melanoma are expected in the second half of 2025, with a potential BLA submission to follow." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-1.htm)) |
| 2H 2025 | [Zepbound (tirzepatide) interim data readout](https://sec-api.dev/pdufa/tirzepatide) | REGN |  | scheduled | "A Phase 2 study of trevogrumab and semaglutide with and without garetosmab is now fully enrolled and a Phase 2 study testing combinations of tirzepatide and mibavademab is ongoing, with initial data expected from both in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-1.htm)) |
| 2H 2025 | [Dupixent (dupilumab) PDUFA date](https://sec-api.dev/pdufa/dupilumab) | REGN |  | scheduled | "- sBLA acceptance for Dupixent in bullous pemphigoid (first half 2025) and FDA decision on sBLA (second half 2025); regulatory submission in European Union (EU) (first half 2025)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/exhibit991q42024.htm)) |
| July 8, 2025 | [Pozelimab + cemdisiran primary completion](https://sec-api.dev/pdufa/pozelimab-cemdisiran) | REGN | Generalized Myasthenia Gravis | completed | "NCT05070858 (A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-08 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05070858)) |
| July 10, 2025 | [Lynozyfic (linvoseltamab) PDUFA date](https://sec-api.dev/pdufa/linvoseltamab) | REGN |  | scheduled | "•The FDA accepted for review the resubmission of the BLA for linvoseltamab, a bispecific antibody targeting BCMA and CD3, in R/R multiple myeloma, with a target action date of July 10, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm)) |
| July 17, 2025 | [Pasatru (garetosmab) primary completion](https://sec-api.dev/pdufa/garetosmab) | REGN | Fibrodysplasia Ossificans Progressiva | completed | "NCT05394116 (A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-17 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05394116)) |
| July 30, 2025 | [Ordspono™ (odronextamab) PDUFA date](https://sec-api.dev/pdufa/odronextamab) | REGN |  | completed, complete response letter | "•The FDA accepted for review the resubmission of the BLA for odronextamab, a bispecific antibody targeting CD20 and CD3, in relapsed/refractory (R/R) follicular lymphoma, with a target action date of July 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm)) |
| July 30, 2025 | [REGENERON PHARMACEUTICALS, INC. PDUFA date](https://sec-api.dev/companies/regn/catalysts) | REGN |  | scheduled | "-FDA decision on BLA for relapsed/refractory FL (target action date of July 30, 2025)" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/872589/000180422025000022/regn-20250331.htm)) |
| July 30, 2025 | [Ordspono™ (odronextamab) complete response letter (CRL)](https://sec-api.dev/pdufa/odronextamab) | REGN |  | completed, complete response letter | "•On July 30, 2025, the FDA issued a Complete Response Letter (CRL) for the BLA for odronextamab, a bispecific antibody targeting CD20 and CD3, in relapsed/refractory follicular lymphoma after two or more lines of systemic therapy, which was also impacted by the Catalent Indiana LLC site inspection (as described above)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/exhibit991q22025.htm)) |
| Aug 2025 | [Eylea® (eylea) PDUFA date](https://sec-api.dev/pdufa/eylea) | REGN | macular edema | completed, complete response letter | "•The Company now expects regulatory approvals to be delayed for its currently pending FDA applications for EYLEA HD (pre-filled syringe, every-four-week dosing, and for the treatment of macular edema following retinal vein occlusion), which have PDUFA dates in August 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/exhibit991q22025.htm)) |
| August 1, 2025 | [REGENERON PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/regn/catalysts) | REGN |  | completed | "Tarrytown, New York (August 1, 2025) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/exhibit991q22025.htm)) |
| August 19, 2025 | [REGENERON PHARMACEUTICALS, INC. PDUFA date](https://sec-api.dev/companies/regn/catalysts) | REGN |  | scheduled | "The FDA target action date is August 19, 2025, following the use of a priority review voucher." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm)) |
| August 26, 2025 | [PAVBLU® (aflibercept) primary completion](https://sec-api.dev/pdufa/aflibercept) | REGN | Neovascular Age-Related Macular Degeneration; Diabetic Macular Edema | completed | "NCT06491914 (A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-08-26 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals; Results First Posted 2026-09-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06491914)) |
| Sep 2025 | [Evkeeza® (evinacumab) FDA approval](https://sec-api.dev/pdufa/evinacumab) | REGN | homozygous familial hypercholesterolemia | completed, approved | "•In September 2025, the FDA approved Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH), extending the already approved indication to include children from age 1 to less than 5 years old." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258925000026/exhibit991q32025.htm)) |
| Sep 2025 | [REGENERON PHARMACEUTICALS, INC. interim data readout](https://sec-api.dev/companies/regn/catalysts) | REGN |  | scheduled | "Final 26-week efficacy and safety results were consistent with the interim data and will be presented at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) in September 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/exhibit991q22025.htm)) |
| September 17, 2025 | [REGN5381 primary completion](https://sec-api.dev/pdufa/regn5381) | REGN | Heart Failure | withdrawn | "NCT06237309 (REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-09-17 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06237309)) |
| September 25, 2025 | [Evkeeza (evinacumab-dgnb) label expansion decision](https://sec-api.dev/pdufa/evinacumab-dgnb) | REGN |  | completed, approved | "BLA761181 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20250925, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product EVKEEZA (EVINACUMAB-DGNB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761181%22)) |
| Oct 2025 | [Libtayo® (cemiplimab) PDUFA date](https://sec-api.dev/pdufa/cemiplimab) | REGN |  | scheduled | "•The FDA accepted for priority review a supplemental Biologics License Application (sBLA) for Libtayo (cemiplimab) in adjuvant CSCC, with a target action date in October 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/exhibit991q22025.htm)) |
| October 8, 2025 | [Libtayo (cemiplimab-rwlc) label expansion decision](https://sec-api.dev/pdufa/cemiplimab-rwlc) | REGN |  | completed, approved | "BLA761097 SUPPL-30 (Efficacy): submission_status AP, submission_status_date 20251008, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product LIBTAYO (CEMIPLIMAB-RWLC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761097%22)) |
| October 9, 2025 | [Praluent (alirocumab) label expansion decision](https://sec-api.dev/pdufa/alirocumab) | REGN |  | completed, approved | "BLA125559 SUPPL-47 (Efficacy): submission_status AP, submission_status_date 20251009, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product PRALUENT (ALIROCUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125559%22)) |
| October 15, 2025 | [REGN5381 primary completion](https://sec-api.dev/pdufa/regn5381) | REGN | Uncontrolled Hypertension | withdrawn | "NCT06833190 (REGN5381 in Adult Participants With Uncontrolled Hypertension): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-15 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06833190)) |
| October 28, 2025 | [REGENERON PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/regn/catalysts) | REGN |  | completed | "Tarrytown, New York (October 28, 2025) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258925000026/exhibit991q32025.htm)) |
| October 29, 2025 | [Libtayo (cemiplimab-rwlc) label expansion decision](https://sec-api.dev/pdufa/cemiplimab-rwlc) | REGN |  | completed, approved | "BLA761097 SUPPL-32 (Efficacy): submission_status AP, submission_status_date 20251029, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product LIBTAYO (CEMIPLIMAB-RWLC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761097%22)) |
| Nov 2025 | [Eylea® (eylea) FDA approval](https://sec-api.dev/pdufa/eylea) | REGN | with RVO with up to every 8-week dosing | completed, approved | "•In November 2025, the FDA approved EYLEA HD for the treatment of patients with RVO with up to every 8-week dosing after an initial monthly dosing period." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258926000004/exhibit991q42025.htm)) |
| Nov 2025 | [Eylea® (eylea) PDUFA date](https://sec-api.dev/pdufa/eylea) | REGN | macular edema | scheduled | "There is also an sBLA under review by the FDA for EYLEA HD every-four-week dosing and for the treatment of macular edema following retinal vein occlusion (RVO), which has a target action date in late November 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258925000026/exhibit991q32025.htm)) |
| November 19, 2025 | [PAVBLU® (aflibercept) label expansion decision](https://sec-api.dev/pdufa/aflibercept) | REGN |  | completed, approved | "BLA761355 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20251119, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product EYLEA HD (AFLIBERCEPT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761355%22)) |
| Dec 2025 | [REGENERON PHARMACEUTICALS, INC. NDA/BLA submission](https://sec-api.dev/companies/regn/catalysts) | REGN | profound genetic hearing loss in children due to variants of the otoferlin | completed | "•In December 2025, the Company submitted a BLA to the FDA for DB-OTO (an AAV-based gene therapy) for the treatment of profound genetic hearing loss in children due to variants of the otoferlin (OTOF) gene." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258926000004/exhibit991q42025.htm)) |
| January 30, 2026 | [REGENERON PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/regn/catalysts) | REGN |  | completed | "Tarrytown, New York (January 30, 2026) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258926000004/exhibit991q42025.htm)) |
| Feb 2026 | [Pasatru (garetosmab) NDA/BLA acceptance](https://sec-api.dev/pdufa/garetosmab) | REGN | with fibrodysplasia ossificans progressiva | completed | "•In February 2026, the FDA accepted for priority review the Biologics License Application (BLA) for garetosmab (an Activin A antibody) for the treatment of adults with fibrodysplasia ossificans progressiva (FOP), which has a target action date in August 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258926000014/exhibit991q12026.htm)) |
| Feb 2026 | [Dupixent (dupilumab) FDA approval](https://sec-api.dev/pdufa/dupilumab) | REGN | and children aged 6 years and older with AFRS | completed, approved | "•In February 2026, the FDA approved Dupixent as the first and only medicine for the treatment of adults and children aged 6 years and older with AFRS." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258926000014/exhibit991q12026.htm)) |
| February 1, 2026 | [REGN7544 primary completion](https://sec-api.dev/pdufa/regn7544) | REGN | Sepsis-Induced Hypotension | completed | "NCT06608901 (A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-01 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06608901)) |
| February 23, 2026 | [Dupixent (dupilumab) label expansion decision](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed, approved | "BLA761055 SUPPL-75 (Efficacy): submission_status AP, submission_status_date 20260223, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22)) |
| February 23, 2026 | [Dupixent (dupilumab) primary completion](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed | "NCT05831176 (A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-02-23 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05831176)) |
| February 28, 2026 | [Dupixent (dupilumab) PDUFA date](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed, approved | "Dupixent sBLA accepted for priority review by the US FDA with a target action date of February 28, 2026; if approved, Dupixent would be the first and only medicine indicated specifically for AFRS, which would be its ninth FDA-approved indication" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312525285701/d895566dex991.htm)) |
| March 12, 2026 | [Fianlimab primary completion](https://sec-api.dev/pdufa/fianlimab) | REGN | Melanoma | completed | "NCT05352672 (Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-12 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05352672)) |
| March 27, 2026 | [REGN9933 primary completion](https://sec-api.dev/pdufa/regn9933) | REGN | Venous Thromboembolism | completed | "NCT06299111 (A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-27 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06299111)) |
| Apr 2026 | [REGENERON PHARMACEUTICALS, INC. PDUFA date](https://sec-api.dev/companies/regn/catalysts) | REGN |  | scheduled | "In addition, the FDA did not act by the April 2026 PDUFA date on the Company's regulatory application for a second contract manufacturer for the PFS; therefore, this application remains pending." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258926000014/exhibit991q12026.htm)) |
| Q2 2026 | [Cemdisiran NDA/BLA acceptance](https://sec-api.dev/pdufa/cemdisiran) | REGN |  | scheduled | "NDA acceptance is anticipated in the second quarter of 2026 with an FDA decision expected in the fourth quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258926000014/exhibit991q12026.htm)) |
| Apr 2026 | [Eylea® (eylea) FDA approval](https://sec-api.dev/pdufa/eylea) | REGN | wet age-related macular degeneration | completed, approved | "•In April 2026, the FDA approved the extension of dosing intervals for EYLEA HD up to every 20 weeks (5 months) for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) following one year of successful response based on visual and anatomic outcomes." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/exhibit991q22026.htm)) |
| April 2, 2026 | [PAVBLU® (aflibercept) label expansion decision](https://sec-api.dev/pdufa/aflibercept) | REGN |  | completed, approved | "BLA761355 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20260402, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product EYLEA HD (AFLIBERCEPT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761355%22)) |
| April 22, 2026 | [Dupixent (dupilumab) label expansion decision](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed, approved | "BLA761055 SUPPL-74 (Efficacy): submission_status AP, submission_status_date 20260422, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22)) |
| April 29, 2026 | [REGENERON PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/regn/catalysts) | REGN |  | completed | "Tarrytown, New York (April 29, 2026) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2026 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258926000014/exhibit991q12026.htm)) |
| May 2, 2026 | [Bremzalerbart primary completion](https://sec-api.dev/pdufa/bremzalerbart) | REGN | Allergic Conjunctivitis | withdrawn | "NCT07309432 (Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-05-02 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07309432)) |
| May 6, 2026 | [Baloncibart primary completion](https://sec-api.dev/pdufa/baloncibart) | REGN | Postural Orthostatic Tachycardia Syndrome (POTS) | completed | "NCT06593600 (Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-06 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06593600)) |
| June 16, 2026 | [Trevogrumab-part a primary completion](https://sec-api.dev/pdufa/trevogrumab-part-a) | REGN | Obesity | completed | "NCT06299098 (A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-06-16 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06299098)) |
| June 17, 2026 | [Ordspono™ (odronextamab) primary completion](https://sec-api.dev/pdufa/odronextamab) | REGN | B-cell Non-Hodgkin Lymphoma (B-NHL) | completed | "NCT03888105 (A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-06-17 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03888105)) |
| 2H 2026 | [REGENERON PHARMACEUTICALS, INC. interim data readout](https://sec-api.dev/companies/regn/catalysts) | REGN |  | scheduled | "A second interim analysis as well as the study's final analysis, if necessary, are anticipated in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258926000014/exhibit991q12026.htm)) |
| 2H 2026 | [REGENERON PHARMACEUTICALS, INC. interim data readout](https://sec-api.dev/companies/regn/catalysts) | REGN |  | scheduled | "Interim data from Phase 3 lead-in cohort anticipated in 2H 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000110465926002691/tm262861d1_ex99-1.htm)) |
| July 9, 2026 | [Mibavademab primary completion](https://sec-api.dev/pdufa/mibavademab) | REGN | Generalized Lipodystrophy | completed | "NCT06548100 (A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-09 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06548100)) |
| July 30, 2026 | [REGENERON PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/regn/catalysts) | REGN |  | completed | "Tarrytown, New York (July 30, 2026) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2026 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/exhibit991q22026.htm)) |
| Aug 2026 | [Pasatru (garetosmab) PDUFA date](https://sec-api.dev/pdufa/garetosmab) | REGN | with fibrodysplasia ossificans progressiva | scheduled | "•In February 2026, the FDA accepted for priority review the Biologics License Application (BLA) for garetosmab (an Activin A antibody) for the treatment of adults with fibrodysplasia ossificans progressiva (FOP), which has a target action date in August 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258926000014/exhibit991q12026.htm)) |
| Aug 2026 | [Pasatru (garetosmab) FDA approval](https://sec-api.dev/pdufa/garetosmab) | REGN |  | completed, approved | "•In August 2026, the FDA approved Pasatru to reduce formation of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258926000032/exhibit991q32026.htm)) |
| Aug to Nov 2026 | [Fianlimab topline data readout](https://sec-api.dev/pdufa/fianlimab) | REGN | Resectable Non-small Cell Lung Cancer | scheduled | "NCT06161441 (A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08-24 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06161441)) |
| August 19, 2026 | [Pasatru (garetosmab-grts) FDA approval](https://sec-api.dev/pdufa/garetosmab-grts) | REGN |  | completed, approved | "Pasatru \| garetosmab-grts \| 8/19/2026 \| To reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| August 2026 | [Fianlimab primary completion](https://sec-api.dev/pdufa/fianlimab) | REGN | Resectable Non-small Cell Lung Cancer | delayed | "NCT06161441 (A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08-24 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06161441)) |
| September 18, 2026 | [PAVBLU® (aflibercept) topline data readout](https://sec-api.dev/pdufa/aflibercept) | REGN | Neovascular Age-Related Macular Degeneration; Diabetic Macular Edema | completed | "NCT06491914 (A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-08-26 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals; Results First Posted 2026-09-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06491914?tab=results)) |
| September 28, 2026 | [Ultomiris® (ravulizumab) primary completion](https://sec-api.dev/pdufa/ravulizumab) | REGN | Paroxysmal Nocturnal Hemoglobinuria | completed | "NCT05133531 (A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-28 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05133531)) |
| Sep to Dec 2026 | [Ultomiris® (ravulizumab) topline data readout](https://sec-api.dev/pdufa/ravulizumab) | REGN | Paroxysmal Nocturnal Hemoglobinuria | scheduled | "NCT05133531 (A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-28 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05133531)) |
| September 29, 2026 | [REGN5381 topline data readout](https://sec-api.dev/pdufa/regn5381) | REGN | Heart Failure | completed | "NCT05353166 (REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-02 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals; Results First Posted 2026-09-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05353166?tab=results)) |
| October 9, 2026 | [Dupixent (dupilumab) primary completion](https://sec-api.dev/pdufa/dupilumab) | REGN | Atopic Dermatitis | completed | "NCT02612454 (Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-09 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02612454)) |
| Oct 2026 to Jan 2027 | [Dupixent (dupilumab) topline data readout](https://sec-api.dev/pdufa/dupilumab) | REGN | Atopic Dermatitis | scheduled | "NCT02612454 (Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-09 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02612454)) |
| October 30, 2026 | [REGENERON PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/regn/catalysts) | REGN |  | completed | "Tarrytown, New York (October 30, 2026) -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial results for the third quarter of 2026 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258926000032/exhibit991q32026.htm)) |
| Nov 2026 | [Cemdisiran PDUFA date](https://sec-api.dev/pdufa/cemdisiran) | REGN |  | scheduled | "The FDA will review the New Drug Application (NDA) under priority review with a target action date in November 2026, following use of a Priority Review Voucher." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/exhibit991q22026.htm)) |
| Nov 2026 to Feb 2027 | [Libtayo® (cemiplimab) topline data readout](https://sec-api.dev/pdufa/cemiplimab) | REGN | Melanoma | scheduled | "NCT06190951 (A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-02 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06190951)) |
| Nov 2026 to Feb 2027 | [Olatorepatide topline data readout](https://sec-api.dev/pdufa/olatorepatide) | REGN | Overweight or Obesity | scheduled | "NCT07431086 (Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-13 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07431086)) |
| November 2026 | [Libtayo® (cemiplimab) primary completion](https://sec-api.dev/pdufa/cemiplimab) | REGN | Melanoma | scheduled | "NCT06190951 (A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-02 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06190951)) |
| November 2026 | [Olatorepatide primary completion](https://sec-api.dev/pdufa/olatorepatide) | REGN | Overweight or Obesity | scheduled | "NCT07431086 (Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-13 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07431086)) |
| Dec 2026 to Mar 2027 | [REGN7999 topline data readout](https://sec-api.dev/pdufa/regn7999) | REGN | Non-Transfusion Dependent Beta-Thalassemia (NTDT) | scheduled | "NCT06421636 (A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-03 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06421636)) |
| Dec 2026 to Mar 2027 | [Praluent (alirocumab) topline data readout](https://sec-api.dev/pdufa/alirocumab) | REGN | Hypercholesterolemia | scheduled | "NCT07477704 (A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07477704)) |
| December 2026 | [REGN7999 primary completion](https://sec-api.dev/pdufa/regn7999) | REGN | Non-Transfusion Dependent Beta-Thalassemia (NTDT) | scheduled | "NCT06421636 (A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-03 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06421636)) |
| December 2026 | [Praluent (alirocumab) primary completion](https://sec-api.dev/pdufa/alirocumab) | REGN | Hypercholesterolemia | scheduled | "NCT07477704 (A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07477704)) |
| 1H 2027 | [Baloncibart trial start](https://sec-api.dev/pdufa/baloncibart) | REGN |  | scheduled | "Additionally, the Company plans to initiate a Phase 3 study in POTS in the first half of 2027, pending regulatory feedback." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258926000032/exhibit991q32026.htm)) |
| Q1 2027 | [Cemdisiran PDUFA date](https://sec-api.dev/pdufa/cemdisiran) | REGN |  | scheduled | "Submit New Drug Application (NDA) for cemdisiran (C5 siRNA therapy) in myasthenia gravis (first quarter 2026) and FDA decision on NDA (fourth quarter 2026/first quarter 2027)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258926000004/exhibit991q42025.htm)) |
| Jan to Apr 2027 | [Fianlimab topline data readout](https://sec-api.dev/pdufa/fianlimab) | REGN | Melanoma | scheduled | "NCT05608291 (A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-15 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05608291)) |
| January 2027 | [Fianlimab primary completion](https://sec-api.dev/pdufa/fianlimab) | REGN | Melanoma | scheduled | "NCT05608291 (A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-15 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05608291)) |
| Feb 2027 | [Ordspono™ (odronextamab) PDUFA date](https://sec-api.dev/pdufa/odronextamab) | REGN |  | scheduled | "•The FDA accepted for review the resubmission of the BLA for Ordspono™ (odronextamab) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), which has a target action date in February 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258926000032/exhibit991q32026.htm)) |
| Feb to May 2027 | [Cenvacibart topline data readout](https://sec-api.dev/pdufa/cenvacibart) | REGN | Venous Thromboembolism (VTE) | scheduled | "NCT07015905 (REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-02-20 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07015905)) |
| Feb to May 2027 | [Cenvacibart topline data readout](https://sec-api.dev/pdufa/cenvacibart) | REGN | Atrial Fibrillation (AF) | scheduled | "NCT07175428 (Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-09 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07175428)) |
| February 2027 | [Cenvacibart primary completion](https://sec-api.dev/pdufa/cenvacibart) | REGN | Atrial Fibrillation (AF) | scheduled | "NCT07175428 (Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-09 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07175428)) |
| February 2027 | [Cenvacibart primary completion](https://sec-api.dev/pdufa/cenvacibart) | REGN | Venous Thromboembolism (VTE) | scheduled | "NCT07015905 (REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-02-20 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07015905)) |
| Mar 2027 | [REGENERON PHARMACEUTICALS, INC. PDUFA date](https://sec-api.dev/companies/regn/catalysts) | REGN |  | scheduled | "There is also a supplemental Biologics License Application (sBLA) under review by the U.S. Food and Drug Administration (FDA), which has a target action date in March 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258926000032/exhibit991q32026.htm)) |
| Mar to Jun 2027 | [Fianlimab topline data readout](https://sec-api.dev/pdufa/fianlimab) | REGN | Melanoma | scheduled | "NCT06246916 (A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-22 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06246916)) |
| March 2027 | [Fianlimab primary completion](https://sec-api.dev/pdufa/fianlimab) | REGN | Melanoma | scheduled | "NCT06246916 (A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-22 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06246916)) |
| May to Aug 2027 | [Cenvacibart topline data readout](https://sec-api.dev/pdufa/cenvacibart) | REGN | Symptomatic Venous Thromboembolism (VTE) | scheduled | "NCT07213778 (REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-17 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07213778)) |
| May 2027 | [Cenvacibart primary completion](https://sec-api.dev/pdufa/cenvacibart) | REGN | Symptomatic Venous Thromboembolism (VTE) | scheduled | "NCT07213778 (REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-17 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07213778)) |
| Jun to Sep 2027 | [Mibavademab topline data readout](https://sec-api.dev/pdufa/mibavademab) | REGN | Monogenic Obesity | scheduled | "NCT07220772 (A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-18 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07220772)) |
| June 2027 | [Mibavademab primary completion](https://sec-api.dev/pdufa/mibavademab) | REGN | Monogenic Obesity | scheduled | "NCT07220772 (A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-18 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07220772)) |
| Sep to Dec 2027 | [Fianlimab topline data readout](https://sec-api.dev/pdufa/fianlimab) | REGN | Advanced Non-Small Cell Lung Cancer | scheduled | "NCT05785767 (A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-09-28 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05785767)) |
| September 2027 | [Fianlimab primary completion](https://sec-api.dev/pdufa/fianlimab) | REGN | Advanced Non-Small Cell Lung Cancer | scheduled | "NCT05785767 (A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-09-28 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05785767)) |
| Jan to Apr 2028 | [Libtayo® (cemiplimab) topline data readout](https://sec-api.dev/pdufa/cemiplimab) | REGN | Cutaneous Squamous Cell Carcinoma | scheduled | "NCT03969004 (Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-07 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03969004)) |
| Jan to Apr 2028 | [BNT116 topline data readout](https://sec-api.dev/pdufa/bnt116) | REGN | Advanced Non-Small Cell Lung Cancer | scheduled | "NCT05557591 (A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-01-26 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05557591)) |
| Jan to Apr 2028 | [Mibavademab topline data readout](https://sec-api.dev/pdufa/mibavademab) | REGN | Functional Hypothalamic Amenorrhea; FHA | scheduled | "NCT07235917 (A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-28 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07235917)) |
| Jan to Apr 2028 | [Olatorepatide topline data readout](https://sec-api.dev/pdufa/olatorepatide) | REGN | Overweight or Obesity | scheduled | "NCT07685808 (Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-21 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07685808)) |
| January 2028 | [Libtayo® (cemiplimab) primary completion](https://sec-api.dev/pdufa/cemiplimab) | REGN | Cutaneous Squamous Cell Carcinoma | scheduled | "NCT03969004 (Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-07 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03969004)) |
| January 2028 | [Olatorepatide primary completion](https://sec-api.dev/pdufa/olatorepatide) | REGN | Overweight or Obesity | scheduled | "NCT07685808 (Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-21 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07685808)) |
| January 2028 | [BNT116 primary completion](https://sec-api.dev/pdufa/bnt116) | REGN | Advanced Non-Small Cell Lung Cancer | scheduled | "NCT05557591 (A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-01-26 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05557591)) |
| January 2028 | [Mibavademab primary completion](https://sec-api.dev/pdufa/mibavademab) | REGN | Functional Hypothalamic Amenorrhea; FHA | scheduled | "NCT07235917 (A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-28 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07235917)) |
| Feb to May 2028 | [Ordspono™ (odronextamab) topline data readout](https://sec-api.dev/pdufa/odronextamab) | REGN | Follicular Lymphoma (FL) | scheduled | "NCT06091254 (A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06091254)) |
| Feb to May 2028 | [REGN13335 topline data readout](https://sec-api.dev/pdufa/regn13335) | REGN | Pulmonary Arterial Hypertension (PAH) | scheduled | "NCT07318597 (Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-27 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07318597)) |
| February 2028 | [REGN13335 primary completion](https://sec-api.dev/pdufa/regn13335) | REGN | Pulmonary Arterial Hypertension (PAH) | scheduled | "NCT07318597 (Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-27 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07318597)) |
| February 2028 | [Ordspono™ (odronextamab) primary completion](https://sec-api.dev/pdufa/odronextamab) | REGN | Follicular Lymphoma (FL) | scheduled | "NCT06091254 (A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06091254)) |
| Mar to Jun 2028 | [Ordspono™ (odronextamab) topline data readout](https://sec-api.dev/pdufa/odronextamab) | REGN | Diffuse Large B-cell Lymphoma (DLBCL) | scheduled | "NCT06091865 (A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-30 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06091865)) |
| March 2028 | [Ordspono™ (odronextamab) primary completion](https://sec-api.dev/pdufa/odronextamab) | REGN | Diffuse Large B-cell Lymphoma (DLBCL) | scheduled | "NCT06091865 (A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-30 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06091865)) |
| Apr to Jul 2028 | [Aln-hsd topline data readout](https://sec-api.dev/pdufa/aln-hsd) | REGN | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | scheduled | "NCT05519475 (A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-04-27 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05519475)) |
| April 2028 | [Aln-hsd primary completion](https://sec-api.dev/pdufa/aln-hsd) | REGN | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | scheduled | "NCT05519475 (A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-04-27 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05519475)) |
| May to Aug 2028 | [Ordspono™ (odronextamab) topline data readout](https://sec-api.dev/pdufa/odronextamab) | REGN | B-Cell Non-Hodgkin Lymphoma (B-NHL) | scheduled | "NCT06230224 (A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06230224)) |
| May to Aug 2028 | [Mibavademab topline data readout](https://sec-api.dev/pdufa/mibavademab) | REGN | Generalized Lipodystrophy | scheduled | "NCT07220785 (Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-19 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07220785)) |
| May 2028 | [Mibavademab primary completion](https://sec-api.dev/pdufa/mibavademab) | REGN | Generalized Lipodystrophy | scheduled | "NCT07220785 (Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-19 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07220785)) |
| May 2028 | [Ordspono™ (odronextamab) primary completion](https://sec-api.dev/pdufa/odronextamab) | REGN | B-Cell Non-Hodgkin Lymphoma (B-NHL) | scheduled | "NCT06230224 (A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06230224)) |
| Jun to Sep 2028 | [Fdc fianlimab+cemiplimab topline data readout](https://sec-api.dev/pdufa/fdc-fianlimab-cemiplimab) | REGN | Head and Neck Squamous Cell Carcinoma (HNSCC) | scheduled | "NCT06769698 (A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06-04 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06769698)) |
| Jun to Sep 2028 | [REGN10597 topline data readout](https://sec-api.dev/pdufa/regn10597) | REGN | Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer | scheduled | "NCT06787612 (Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06787612)) |
| Jun to Sep 2028 | [Dupixent (dupilumab) topline data readout](https://sec-api.dev/pdufa/dupilumab) | REGN | Eosinophilic Esophagitis (EoE) | scheduled | "NCT07112378 (A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-19 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07112378)) |
| June 2028 | [Fdc fianlimab+cemiplimab primary completion](https://sec-api.dev/pdufa/fdc-fianlimab-cemiplimab) | REGN | Head and Neck Squamous Cell Carcinoma (HNSCC) | scheduled | "NCT06769698 (A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06-04 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06769698)) |
| June 2028 | [Dupixent (dupilumab) primary completion](https://sec-api.dev/pdufa/dupilumab) | REGN | Eosinophilic Esophagitis (EoE) | scheduled | "NCT07112378 (A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-19 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07112378)) |
| June 2028 | [REGN10597 primary completion](https://sec-api.dev/pdufa/regn10597) | REGN | Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer | scheduled | "NCT06787612 (Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06787612)) |
| Jul to Oct 2028 | [Pozelimab topline data readout](https://sec-api.dev/pdufa/pozelimab) | REGN | Age-related Macular Degeneration (AMD); Geographic Atrophy (GA) | scheduled | "NCT06541704 (A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-31 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06541704)) |
| July 2028 | [Pozelimab primary completion](https://sec-api.dev/pdufa/pozelimab) | REGN | Age-related Macular Degeneration (AMD); Geographic Atrophy (GA) | scheduled | "NCT06541704 (A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-31 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06541704)) |
| Oct 2028 to Jan 2029 | [Pozelimab topline data readout](https://sec-api.dev/pdufa/pozelimab) | REGN | Paroxysmal Nocturnal Hemoglobinuria | scheduled | "NCT05744921 (A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-10 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05744921)) |
| Oct 2028 to Jan 2029 | [Aln-ang3 topline data readout](https://sec-api.dev/pdufa/aln-ang3) | REGN | Diabetic Kidney Disease (DKD) | scheduled | "NCT07271186 (Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-10-13 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07271186)) |
| October 2028 | [Pozelimab primary completion](https://sec-api.dev/pdufa/pozelimab) | REGN | Paroxysmal Nocturnal Hemoglobinuria | scheduled | "NCT05744921 (A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-10 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05744921)) |
| October 2028 | [Aln-ang3 primary completion](https://sec-api.dev/pdufa/aln-ang3) | REGN | Diabetic Kidney Disease (DKD) | scheduled | "NCT07271186 (Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-10-13 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07271186)) |
| Nov 2028 to Feb 2029 | [Olatorepatide topline data readout](https://sec-api.dev/pdufa/olatorepatide) | REGN | Hidradenitis Suppurativa | scheduled | "NCT07830329 (Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-11-24 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07830329)) |
| November 2028 | [Olatorepatide primary completion](https://sec-api.dev/pdufa/olatorepatide) | REGN | Hidradenitis Suppurativa | scheduled | "NCT07830329 (Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-11-24 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07830329)) |
| Dec 2028 to Mar 2029 | [Olatorepatide topline data readout](https://sec-api.dev/pdufa/olatorepatide) | REGN | Overweight or Obesity Without Diabetes | scheduled | "NCT07896265 (Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-12-19 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07896265)) |
| December 2028 | [Olatorepatide primary completion](https://sec-api.dev/pdufa/olatorepatide) | REGN | Overweight or Obesity Without Diabetes | scheduled | "NCT07896265 (Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-12-19 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07896265)) |
| Jan to Apr 2029 | [Aln-cideb topline data readout](https://sec-api.dev/pdufa/aln-cideb) | REGN | Metabolic Dysfunction-Associated Steatohepatitis; MASH | scheduled | "NCT07631637 (Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07631637)) |
| January 2029 | [Aln-cideb primary completion](https://sec-api.dev/pdufa/aln-cideb) | REGN | Metabolic Dysfunction-Associated Steatohepatitis; MASH | scheduled | "NCT07631637 (Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07631637)) |
| Mar to Jun 2029 | [Cenvacibart topline data readout](https://sec-api.dev/pdufa/cenvacibart) | REGN | Atrial Fibrillation (AF) | scheduled | "NCT07430956 (Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-28 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07430956)) |
| Mar to Jun 2029 | [Aln-cideb topline data readout](https://sec-api.dev/pdufa/aln-cideb) | REGN | Metabolic Dysfunction-Associated Steatotic Liver Disease; MASLD | scheduled | "NCT07854782 (Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-03 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07854782)) |
| March 2029 | [Aln-cideb primary completion](https://sec-api.dev/pdufa/aln-cideb) | REGN | Metabolic Dysfunction-Associated Steatotic Liver Disease; MASLD | scheduled | "NCT07854782 (Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-03 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07854782)) |
| March 2029 | [Cenvacibart primary completion](https://sec-api.dev/pdufa/cenvacibart) | REGN | Atrial Fibrillation (AF) | scheduled | "NCT07430956 (Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-28 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07430956)) |
| May to Aug 2029 | [Lynozyfic (linvoseltamab) topline data readout](https://sec-api.dev/pdufa/linvoseltamab) | REGN | Relapsed and/or Refractory Multiple Myeloma (RRMM) | scheduled | "NCT07222761 (A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05-21 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07222761)) |
| May to Aug 2029 | [Regn-2cat topline data readout](https://sec-api.dev/pdufa/regn-2cat) | REGN | Allergic Conjunctivitis | scheduled | "NCT07675811 (A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05-31 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07675811)) |
| May to Aug 2029 | [Aln-cideb topline data readout](https://sec-api.dev/pdufa/aln-cideb) | REGN | Alcohol-Associated Liver Disease; ALD | scheduled | "NCT07933328 (Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-05-07 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07933328)) |
| May 2029 | [Aln-cideb primary completion](https://sec-api.dev/pdufa/aln-cideb) | REGN | Alcohol-Associated Liver Disease; ALD | scheduled | "NCT07933328 (Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-05-07 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07933328)) |
| May 2029 | [Lynozyfic (linvoseltamab) primary completion](https://sec-api.dev/pdufa/linvoseltamab) | REGN | Relapsed and/or Refractory Multiple Myeloma (RRMM) | scheduled | "NCT07222761 (A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05-21 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07222761)) |
| May 2029 | [Regn-2cat primary completion](https://sec-api.dev/pdufa/regn-2cat) | REGN | Allergic Conjunctivitis | scheduled | "NCT07675811 (A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05-31 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07675811)) |
| Jun to Sep 2029 | [Cenvacibart topline data readout](https://sec-api.dev/pdufa/cenvacibart) | REGN | Venous Thromboembolism (VTE) | scheduled | "NCT07697599 (Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-25 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07697599)) |
| June 2029 | [Cenvacibart primary completion](https://sec-api.dev/pdufa/cenvacibart) | REGN | Venous Thromboembolism (VTE) | scheduled | "NCT07697599 (Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-25 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07697599)) |
| Jul to Oct 2029 | [Ordspono™ (odronextamab) topline data readout](https://sec-api.dev/pdufa/odronextamab) | REGN | Follicular Lymphoma (FL) | scheduled | "NCT06097364 (A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-07-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06097364)) |
| July 2029 | [Ordspono™ (odronextamab) primary completion](https://sec-api.dev/pdufa/odronextamab) | REGN | Follicular Lymphoma (FL) | scheduled | "NCT06097364 (A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-07-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06097364)) |
| Aug to Nov 2029 | [Cenvacibart topline data readout](https://sec-api.dev/pdufa/cenvacibart) | REGN | Peripheral Artery Disease (PAD) | scheduled | "NCT07318610 (Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-18 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07318610)) |
| August 2029 | [Cenvacibart primary completion](https://sec-api.dev/pdufa/cenvacibart) | REGN | Peripheral Artery Disease (PAD) | scheduled | "NCT07318610 (Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-18 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07318610)) |
| Sep to Dec 2029 | [Cenvacibart topline data readout](https://sec-api.dev/pdufa/cenvacibart) | REGN | Atrial Fibrillation (AF) | scheduled | "NCT07626411 (Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-11 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07626411)) |
| September 2029 | [Cenvacibart primary completion](https://sec-api.dev/pdufa/cenvacibart) | REGN | Atrial Fibrillation (AF) | scheduled | "NCT07626411 (Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-11 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07626411)) |
| Dec 2029 to Mar 2030 | [REGN10597 topline data readout](https://sec-api.dev/pdufa/regn10597) | REGN | Non Small Cell Lung Cancer; NSCLC | scheduled | "NCT06465329 (A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-12-04 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06465329)) |
| Dec 2029 to Mar 2030 | [Cenvacibart topline data readout](https://sec-api.dev/pdufa/cenvacibart) | REGN | Secondary Stroke | scheduled | "NCT07876492 (A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-12-15 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07876492)) |
| December 2029 | [REGN10597 primary completion](https://sec-api.dev/pdufa/regn10597) | REGN | Non Small Cell Lung Cancer; NSCLC | scheduled | "NCT06465329 (A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-12-04 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06465329)) |
| December 2029 | [Cenvacibart primary completion](https://sec-api.dev/pdufa/cenvacibart) | REGN | Secondary Stroke | scheduled | "NCT07876492 (A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-12-15 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07876492)) |
| Jan to Apr 2030 | [Fianlimab topline data readout](https://sec-api.dev/pdufa/fianlimab) | REGN | Non-small Cell Lung Cancer | scheduled | "NCT05800015 (A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-01-16 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05800015)) |
| Jan to Apr 2030 | [Pozelimab topline data readout](https://sec-api.dev/pdufa/pozelimab) | REGN | Paroxysmal Nocturnal Hemoglobinuria | scheduled | "NCT07154745 (A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-01-18 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07154745)) |
| Jan to Apr 2030 | [Cenvacibart topline data readout](https://sec-api.dev/pdufa/cenvacibart) | REGN | Cancer-Associated Thrombosis (CAT) | scheduled | "NCT07410117 (REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-01-23 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07410117)) |
| January 2030 | [Fianlimab primary completion](https://sec-api.dev/pdufa/fianlimab) | REGN | Non-small Cell Lung Cancer | scheduled | "NCT05800015 (A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-01-16 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05800015)) |
| January 2030 | [Pozelimab primary completion](https://sec-api.dev/pdufa/pozelimab) | REGN | Paroxysmal Nocturnal Hemoglobinuria | scheduled | "NCT07154745 (A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-01-18 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07154745)) |
| January 2030 | [Cenvacibart primary completion](https://sec-api.dev/pdufa/cenvacibart) | REGN | Cancer-Associated Thrombosis (CAT) | scheduled | "NCT07410117 (REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-01-23 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07410117)) |
| Mar to Jun 2030 | [Aln-pnp topline data readout](https://sec-api.dev/pdufa/aln-pnp) | REGN | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | scheduled | "NCT07527910 (A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-03-15 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07527910)) |
| March 2030 | [Aln-pnp primary completion](https://sec-api.dev/pdufa/aln-pnp) | REGN | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | scheduled | "NCT07527910 (A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-03-15 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07527910)) |
| May to Aug 2030 | [Libtayo® (cemiplimab) topline data readout](https://sec-api.dev/pdufa/cemiplimab) | REGN | Cutaneous Squamous Cell Carcinoma (CSCC) | scheduled | "NCT06585410 (Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-05-03 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06585410)) |
| May 2030 | [Libtayo® (cemiplimab) primary completion](https://sec-api.dev/pdufa/cemiplimab) | REGN | Cutaneous Squamous Cell Carcinoma (CSCC) | scheduled | "NCT06585410 (Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-05-03 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06585410)) |
| Jun to Sep 2030 | [Ubamatamab topline data readout](https://sec-api.dev/pdufa/ubamatamab) | REGN |  | scheduled | "NCT07154290 (A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-06-10 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07154290)) |
| June 2030 | [Ubamatamab primary completion](https://sec-api.dev/pdufa/ubamatamab) | REGN |  | scheduled | "NCT07154290 (A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-06-10 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07154290)) |
| Jul to Oct 2030 | [Pasatru (garetosmab) topline data readout](https://sec-api.dev/pdufa/garetosmab) | REGN | Fibrodysplasia Ossificans Progressiva; FOP | scheduled | "NCT07559513 (A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-07-08 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07559513)) |
| July 2030 | [Pasatru (garetosmab) primary completion](https://sec-api.dev/pdufa/garetosmab) | REGN | Fibrodysplasia Ossificans Progressiva; FOP | scheduled | "NCT07559513 (A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-07-08 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07559513)) |
| Oct 2030 to Jan 2031 | [Fianlimab+cemiplimab topline data readout](https://sec-api.dev/pdufa/fianlimab-cemiplimab) | REGN | Melanoma | scheduled | "NCT06848088 (A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-10-09 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06848088)) |
| October 2030 | [Fianlimab+cemiplimab primary completion](https://sec-api.dev/pdufa/fianlimab-cemiplimab) | REGN | Melanoma | scheduled | "NCT06848088 (A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-10-09 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06848088)) |
| Nov 2030 to Feb 2031 | [Libtayo® (cemiplimab) topline data readout](https://sec-api.dev/pdufa/cemiplimab) | REGN | Locally Advanced Basal Cell Carcinoma | scheduled | "NCT07808515 (A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2030-11-13 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07808515)) |
| November 2030 | [Libtayo® (cemiplimab) primary completion](https://sec-api.dev/pdufa/cemiplimab) | REGN | Locally Advanced Basal Cell Carcinoma | scheduled | "NCT07808515 (A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2030-11-13 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07808515)) |

## Drugs

- [PAVBLU® (aflibercept)](https://sec-api.dev/pdufa/aflibercept): with neovascular, eye disorders, wet amd and dme, neovascular, Neovascular Age-Related Macular Degeneration
- [Praluent (alirocumab)](https://sec-api.dev/pdufa/alirocumab): Hypercholesterolemia
- [Aln-ang3](https://sec-api.dev/pdufa/aln-ang3): Diabetic Kidney Disease (DKD)
- [Aln-cideb](https://sec-api.dev/pdufa/aln-cideb): Alcohol-Associated Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, Metabolic Dysfunction-Associated Steatotic Liver Disease
- [Aln-hsd](https://sec-api.dev/pdufa/aln-hsd): Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
- [Aln-pnp](https://sec-api.dev/pdufa/aln-pnp): Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- [Inmazeb (atoltivimab; maftivimab; odesivimab)](https://sec-api.dev/pdufa/atoltivimab-maftivimab-odesivimab): 
- [Baloncibart](https://sec-api.dev/pdufa/baloncibart): Postural Orthostatic Tachycardia Syndrome (POTS)
- [BNT116](https://sec-api.dev/pdufa/bnt116): Advanced Non-Small Cell Lung Cancer
- [Bremzalerbart](https://sec-api.dev/pdufa/bremzalerbart): Allergic Conjunctivitis
- [Cemdisiran](https://sec-api.dev/pdufa/cemdisiran): 
- [Libtayo® (cemiplimab)](https://sec-api.dev/pdufa/cemiplimab): Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Carcinoma, Melanoma, Locally Advanced Basal Cell Carcinoma
- [Libtayo (cemiplimab-rwlc)](https://sec-api.dev/pdufa/cemiplimab-rwlc): 
- [Cenvacibart](https://sec-api.dev/pdufa/cenvacibart): Cancer-Associated Thrombosis (CAT), Venous Thromboembolism (VTE), Atrial Fibrillation (AF), Secondary Stroke, Peripheral Artery Disease (PAD), Symptomatic Venous Thromboembolism (VTE)
- [Dupixent (dupilumab)](https://sec-api.dev/pdufa/dupilumab): and children aged 6 years and older with afrs, with bullous pemphigoid, and adolescents aged 12 years and older with csu, and adolescents aged 12 years and older with chronic spontaneous urticaria, Lichen Simplex Chronicus, Eosinophilic Esophagitis (EoE), Prurigo Nodularis, Eosinophilic Gastritis (EoG)
- [Evkeeza® (evinacumab)](https://sec-api.dev/pdufa/evinacumab): homozygous familial hypercholesterolemia
- [Evkeeza (evinacumab-dgnb)](https://sec-api.dev/pdufa/evinacumab-dgnb): 
- [Eylea® (eylea)](https://sec-api.dev/pdufa/eylea): macular edema, neovascular, wet age-related macular degeneration, with rvo with up to every 8-week dosing
- [Fdc fianlimab+cemiplimab](https://sec-api.dev/pdufa/fdc-fianlimab-cemiplimab): Head and Neck Squamous Cell Carcinoma (HNSCC)
- [Fianlimab](https://sec-api.dev/pdufa/fianlimab): Melanoma, Non-small Cell Lung Cancer, Resectable Non-small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer
- [Fianlimab+cemiplimab](https://sec-api.dev/pdufa/fianlimab-cemiplimab): Melanoma
- [Pasatru (garetosmab)](https://sec-api.dev/pdufa/garetosmab): with fibrodysplasia ossificans progressiva, Fibrodysplasia Ossificans Progressiva
- [Pasatru (garetosmab-grts)](https://sec-api.dev/pdufa/garetosmab-grts): 
- [Lynozyfic (linvoseltamab)](https://sec-api.dev/pdufa/linvoseltamab): Relapsed and/or Refractory Multiple Myeloma (RRMM)
- [Lynozyfic (linvoseltamab-gcpt)](https://sec-api.dev/pdufa/linvoseltamab-gcpt): 
- [Mibavademab](https://sec-api.dev/pdufa/mibavademab): Generalized Lipodystrophy, Monogenic Obesity, Functional Hypothalamic Amenorrhea
- [Ordspono™ (odronextamab)](https://sec-api.dev/pdufa/odronextamab): relapsed/refractory fl and dlbcl due, B-cell Non-Hodgkin Lymphoma (B-NHL), Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL)
- [Olatorepatide](https://sec-api.dev/pdufa/olatorepatide): Hidradenitis Suppurativa, Overweight or Obesity, Overweight or Obesity Without Diabetes
- [Pozelimab](https://sec-api.dev/pdufa/pozelimab): Age-related Macular Degeneration (AMD), Paroxysmal Nocturnal Hemoglobinuria
- [Veopoz (pozelimab-bbfg)](https://sec-api.dev/pdufa/pozelimab-bbfg): 
- [Pozelimab + cemdisiran](https://sec-api.dev/pdufa/pozelimab-cemdisiran): Generalized Myasthenia Gravis
- [Regn-2cat](https://sec-api.dev/pdufa/regn-2cat): Allergic Conjunctivitis
- [REGN10597](https://sec-api.dev/pdufa/regn10597): Non Small Cell Lung Cancer, Ovarian Cancer
- [REGN13335](https://sec-api.dev/pdufa/regn13335): Pulmonary Arterial Hypertension (PAH)
- [REGN1908](https://sec-api.dev/pdufa/regn1908): Allergic Conjunctivitis
- [REGN5381](https://sec-api.dev/pdufa/regn5381): Uncontrolled Hypertension, Heart Failure
- [REGN7544](https://sec-api.dev/pdufa/regn7544): Sepsis-Induced Hypotension
- [REGN7999](https://sec-api.dev/pdufa/regn7999): Non-Transfusion Dependent Beta-Thalassemia (NTDT)
- [REGN9933](https://sec-api.dev/pdufa/regn9933): Venous Thromboembolism
- [Trevogrumab-part a](https://sec-api.dev/pdufa/trevogrumab-part-a): Obesity
- [Ubamatamab](https://sec-api.dev/pdufa/ubamatamab): Non Small Cell Lung Cancer

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/regn/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "REGN catalysts: REGENERON PHARMACEUTICALS, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/regn/catalysts

```bibtex
@misc{secapidev_companies_regn_catalysts_20261116,
  title        = {REGN catalysts: REGENERON PHARMACEUTICALS, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/regn/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_regn_catalysts_20261116","title":"REGN catalysts: REGENERON PHARMACEUTICALS, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/regn/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
